今日观察！碳酸锂价格承压回调 储能市场格局或迎变局

碳酸锂价格承压回调 储能市场格局或迎变局

上海 - 2024年6月18日，受下游需求疲软和新增产能释放影响，碳酸锂价格近期出现明显回调。业内人士普遍认为，碳酸锂价格短期内或将维持震荡走势，但长期来看仍将保持坚挺态势。

碳酸锂价格冲高回落

2023年下半年以来，受新能源汽车市场强劲增长以及动力电池产业链需求旺盛影响，碳酸锂价格持续飙升，一度突破50万元/吨。然而，进入2024年第二季度，随着下游需求转弱以及新增产能释放，碳酸锂价格开始出现回落迹象。

数据显示，截至2024年6月18日，电池级碳酸锂价格为48万元/吨，较3月份峰值51.5万元/吨下跌6.8%。业内人士分析认为，碳酸锂价格回调主要有以下几个原因：

• **下游需求疲软。**随着新能源汽车补贴政策退坡以及原材料价格上涨，新能源汽车整车价格明显上调，终端消费需求受到抑制。此外，动力电池企业受利润压迫，对碳酸锂采购有所放缓。
• **新增产能释放。**近年来，国内碳酸锂产能快速扩张，2024年预计新增产能超过50万吨。随着新项目的陆续投产，市场供应将逐渐增加。

储能市场格局或迎变局

碳酸锂价格回调对储能市场的影响也值得关注。作为储能电池的核心原材料，碳酸锂价格变化将直接影响储能项目的成本。

有分析人士指出，碳酸锂价格回调有利于降低储能项目成本，促进储能市场发展。但同时也可能导致部分盈利能力较弱的储能企业利润压缩，甚至陷入亏损。

长期来看 碳酸锂价格仍将维持坚挺

尽管短期内碳酸锂价格可能承压，但业内人士普遍认为，长期来看碳酸锂价格仍将维持坚挺态势。

主要原因包括：

• **新能源汽车市场需求旺盛。**预计未来几年新能源汽车市场将保持快速增长，动力电池需求将持续增加。
• **锂资源供应紧张。**全球锂资源储量有限，短期内难以大幅扩充。

总体而言，碳酸锂价格未来走势仍将受多种因素影响，存在一定不确定性。但从长期来看，随着新能源产业的快速发展，碳酸锂市场需求将保持旺盛，价格有望维持高位。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.